Medical/Pharmaceuticals
I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis
SHANGHAI and GAITHERSBURG, Md., April 26, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced positive topline results from its regional multi-center...
2021-04-26 19:00
1637
Peijia Medical's TaurusOne® Transcatheter Aortic Valve Replacement System Approved for Commercialization
SUZHOU, China, April 24, 2021 /PRNewswire/ -- A new interventional solution from China for structural heart disease is about to be launched onto the market. Recently, TaurusOne® Transcatheter Aortic Valve Replacement System (hereinafter referred to as "TaurusOne®") developed by Peijia Medical (Suz...
2021-04-25 08:53
2532
Ronovo Surgical Completes Series A Financing, Aims to Transform Surgery with Innovations Focused on Simplicity, Precision and Intelligence.
SHANGHAI, April 23, 2021 /PRNewswire/ -- Ronovo Surgical, an emerging medtech company focused on innovating minimally invasive (MIS) and digital surgery to address the tremendous needs of the Chinese surgical market, recently announced successful closing of Series A financing. Developed by renow...
2021-04-23 22:00
3058
Jolly Good and Teijin Pharma Form a Partnership to Develop VR Digital Therapeutics for Depression
TOKYO, April 23, 2021 /PRNewswire/ -- Jolly Good Inc. ("Jolly Good") and Teijin Pharma Ltd. ("Teijin Pharma") have signed a business partnership agreement to develop VR digital therapeutics ("VR DTx") for Major Depressive Disorder (MDD). Together, they will promote the development of VR DTx for d...
2021-04-23 21:00
2595
Wuxi Strives to Build a World-class Biomedical Industry Chain
WUXI, China, April 22, 2021 /PRNewswire/ -- From April 21 to 23, the 2021 Taihu Bay Future Healthcare Conference was held in Wuxi,China. More than 160 experts including Hejie, Fan Chunhai and many other academicians carried out forward-looking, authoritative, and predictive exchanges and dialogue...
2021-04-22 19:06
953
111 to Announce First Quarter 2021 Unaudited Financial Results on May 19, 2021 - Conference Call to Follow
SHANGHAI, April 21, 2021 /PRNewswire/ – 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results...
2021-04-21 20:00
2081
Seed Health Closes $40 Million in Series A Financing to Launch New Categories, Accelerate Global Distribution and Expand Clinical Research
LOS ANGELES, April 21, 2021 /PRNewswire/ -- Seed Health, a microbial sciences company developing next-generation probiotic applications and live biotherapeutics, today announced the close of a $40 million Series A financing led by impact investor,The Craftory, alongside TechBio investor ARTIS Ven...
2021-04-21 20:00
2722
Samsung Biologics Celebrates Its 10th Anniversary with Its Mission, "Driven. For Life."
INCHEON, South Korea, April 21, 2021 /PRNewswire/ -- Samsung Biologics, the
world's leading contract development and manufacturing organization, celebrated
the 10th anniversary of its founding today at its global headquarters in
Songdo, Incheon via a virtual ceremony.
2021-04-21 19:00
1326
China Biologic Announces Completion of Going Private Transaction
BEIJING, April 20, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced the completion of its merger (the "Merger") with CBPO Group Limited ("Merger...
2021-04-21 04:30
4509
Transcenta Received IND Clearance from US FDA for Initiating Phase I Clinical Trial for its Bi-functional Anti-PD-L1/TGF-β Antibody TST005
SUZHOU, China, April 20, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced that it has received clearance of i...
2021-04-20 20:54
1012
AACR 2021-ImmVira presents the preclinical study results of MVR-T3011 via intravenous administration
SHENZHEN, China, April 19, 2021 /PRNewswire/ -- On April 15, 2021, ImmVira presents the preclinical study results of MVR-T3011 via intravenous administration through publication in a virtual poster at the AACR annual meeting. MVR-T3011 is a replication competent and genetically modified oncolyti...
2021-04-20 08:30
1465
Terumo Blood and Cell Technologies and CSL Plasma Announce Collaboration to Deliver New Plasma Collection Platform
LAKEWOOD, Colo. and BOCA RATON, Fla., April 19, 2021 /PRNewswire/ -- Terumo Blood and Cell Technologies and CSL Plasma today announce a collaboration to deliver a new plasma collection platform at CSL Plasma U.S. collection centers. A clinical trial of the investigational plasmapheresis device ...
2021-04-20 05:00
2109
China Pharma Expects Considerable Increase in Growth Opportunities Related to Hainan Free Trade Port
HAIKOU, China, April 19, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, commented on the policy statements in "Several Special Measures to Support the Construction of Hainan Free Trade Port to Rel...
2021-04-19 20:30
2860
CNPharm has succeeded in maintaining IC100 for 24 hours with one injection
- Trail-blazing diversification of the repurposing of Niclosamide - Full-scale clinical preparation of injections for severely ill patients SEOUL, South Korea, April 19, 2021 /PRNewswire/ -- Hyundai Bioscience (Symbol 048410), a KOSDAQ listed company, announced on the 19th that its major sharehol...
2021-04-19 20:15
1388
Porton Biologics Announces Closing Series-A Financing to Drive Commercial Production of Gene and Cell Therapy
SUZHOU, China, April 19, 2021 /PRNewswire/ -- On April 16, 2021, Suzhou Porton BiologicsLtd. (hereinafter referred to as Porton Biologics), a subsidiary of Porton Pharma Solutions Ltd. (hereinafter referred to as Porton Pharma Solutions) (300363.SZ), which focuses on gene and cell therapy CDMO se...
2021-04-19 20:00
4262
PharmAbcine announces Clinical Trial Collaboration with MSD for the Phase II study in mTNBC
DAEJEON, South Korea, April 19, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company has entered into an agreement with MSD to initiate a Phase II combination trial of olin...
2021-04-19 20:00
1323
Transcenta Announced Successful First Patient Dosed in Phase I Clinical Study of TST001 Combined with CAPOX for the Treatment of Patients with First-line Locally Advanced Unresectable or Metastatic Gastric Cancer
SUZHOU, China, April 18, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced the first patient has been success...
2021-04-19 08:00
1618
Kintor Pharmaceuticals Announced Successful Dosing of the First Batch of Patients for Acne Vulgaris Phase I/II Clinical Trial of Pyrilutamide
SUZHOU, China, April 16, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing small molecule and biological therapeutics, announced today the clinical trial of Pyrilutamide as a treatment for the acne vulgaris has completed the first b...
2021-04-16 18:29
5027
Transcenta Announced Presentation of Preclinical Data of TST005 at 2021 AACR Virtual Annual Meeting
SUZHOU, China, April 15, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, presented preclinical data of TST005, a bi-functio...
2021-04-16 08:00
1196
Kintor Pharmaceutical Announces AR-PROTAC (GT20029) Approved for Acne and Androgenic Alopecia Clinical Trials in China
SUZHOU, China, April 15, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (stock code 9939.HK, "Kintor Pharmaceutical" or the "Company"), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that it has received approval from t...
2021-04-15 18:20
4731
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Multiple achievements made in China-Hungary BRI conference
[Picked up by 317 media titles]
2024-05-03 06:59
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 295 media titles]
2024-04-30 10:11
Xinhua president, Hungarian economy minister vow to bolster media cooperation
[Picked up by 287 media titles]
2024-05-03 06:25TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 262 media titles]
2024-05-02 01:21
Most Read
/C O R R E C T I O N -- Addverb/
2024-05-03 20:26
9352
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
2024-04-30 10:11
6994
Multiple achievements made in China-Hungary BRI conference
2024-05-03 06:59
6107
Xinhua president, Hungarian economy minister vow to bolster media cooperation
2024-05-03 06:25
5730
